Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma

Authors: Kalsi, Jas; Harland, Stephen J; Feneley, Mark R

Source: Expert Opinion on Drug Delivery, Volume 5, Number 1, January 2008 , pp. 137-145(9)

Publisher: Informa Healthcare

Buy & download fulltext article:

OR

Price: $99.00 plus tax (Refund Policy)

Abstract:

This article reviews the use and application of electromotive drug administration for the intravesical treatment of bladder cancer. Strong evidence supports the use of passive intravesical chemotherapy in the management of non-muscle invasive bladder cancer. More recently, two published randomised trials have shown therapeutic advantage with protocols that use electromotive drug administration to enhance urothelial penetration of intravesical mitomycin C. The results suggest that the passive intravesical administration of chemotherapeutic drugs may be suboptimal. Further studies are required to demonstrate the feasibility and advantage of electromotive intravesical mitomycin C in the wider uro-oncological community.

Keywords: chemotherapy; electromotive drug administration; intravesical; mitomycin C; non-invasive bladder cancer; transitional cell carcinoma

Document Type: Research article

DOI: http://dx.doi.org/10.1517/17425247.5.1.137

Affiliations: 1: 2Senior Lecturer in Oncology, University College London, London, UK

Publication date: 2008-01-01

More about this publication?
Related content

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page